Larotrectinib (Vitrakvi®)

Larotrectinib (Vitrakvi®) was added to the High Tech Arrangement on 1 June 2023. A Managed Access Protocol (MAP) is in place for larotrectinib. This outlines the criteria that must be satisfied in order for a patient to be recommended for reimbursement of larotrectinib under the High Tech Arrangement.

The prescribing of larotrectinib under the High Tech Arrangement is confined to consultant medical oncologists registered with the Irish Medical Council, who have agreed to the terms of this MAP and who have been approved by the HSE.

The clinician must submit an application for individual reimbursement approval for each patient. Applications for individual reimbursement approval will only be considered from approved clinicians.

A copy of the HSE-Managed Access Protocol for larotrectinib and the application form for individual reimbursement approval can be found in the Related Files section below.

For further information, please contact